TickerTalks
Browse all tickers →
TickerTalks›$SYK
SYSYK

Stryker Corporation

$SYK·$123B·Medical - Devices·Healthcare
$314.58-1.4%YTD-9.1%1Y-17.6%
Mentions · last 7 days
2026-07-14: 169 posts2026-07-15: 186 posts2026-07-16: 187 posts2026-07-17: 127 posts2026-07-18: 3 posts2026-07-19: 11 posts2026-07-20: 11 posts715+0%
Price updated 40m ago·X counts updated 23h ago
SYSYK
$SYKStryker Corporation
$314.58-1.43%715 posts+0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $SYK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-21

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Med-device compounder just launched Mako RPS for knee robotics — Q2 earnings this month tests the growth trajectory.

Stryker is the diversified medical-device leader in orthopedics, robotic surgery (Mako) and neurotechnology — a defensive-growth compounder range-bound as procedure-volume growth normalized and the market waited for the next Mako refresh cycle.

  • Growth is real but modest: Q1 2026 revenue of $6.02B was up 2.6% YoY (below the 8-9% Stryker averaged pre-2025) and Q4 was +11.4% — the Q1 deceleration was seasonal, and FY26 consensus $27.3B implies mid-single-digit growth resuming.
  • Beat cadence has been consistent: EPS surprises of +2.0%, +1.6%, +1.9% but a -12.8% miss in Q1 — management out-earns consensus in normal quarters but occasionally gets caught by procedure-volume timing.
  • The Mako RPS launch is the specific product catalyst: full US market release of Mako RPS for robotic knee surgery on July 16 — expands Stryker's dominant Mako platform into a new indication and reinforces the moat versus Chinese robotic competitors.
  • Valuation reflects mature quality: 37x TTM and 21x forward on FY26 consensus $14.98 EPS is fair for a defensive-growth medtech leader — a discount to Intuitive Surgical (50x) but a premium to Zimmer Biomet.

July 30 Q2 — FY26 EPS guide holding $14.98 and Mako RPS placement commentary matter most. What extends the run: a beat-plus-raise like Abbott plus Mako placement acceleration; what invalidates: another procedure-volume disappointment or a walked-back FY26 guide.

What to watch: July 30 Q2 earnings — FY26 EPS guide holding $14.98 and Mako RPS placement commentary matter most. A beat-plus-raise like Abbott plus Mako placement acceleration is the specific extension catalyst.

On the calendar: 2026-07-30 — Q2 earnings

sentiment missing

Read the AI verdict + X sentiment for $SYK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $SYK.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $SYK

Direct beneficiary — Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing imp; core revenue tied directly to the primary demand driver in medical - devices.

Industry benchmark

15-name peer basket
-13.3%YTD
-4.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
9.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
15.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
63.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$2.60$2.98-12.8%
Q4 2025Jan 29, 2026$4.47$4.40+1.6%
Q3 2025Oct 30, 2025$3.19$3.13+1.9%
Q2 2025Jul 31, 2025$3.13$3.07+2.0%
Next earningsThu, Jul 30·consensus EPS $3.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.0B+2.6%63.3%15.5%$1.95$415.0M
Q4 FY25$7.2B+11.4%65.2%27.3%$2.21$1.9B
Q3 FY25$6.1B+10.2%63.6%18.7%$2.25$1.4B
Q2 FY25$6.0B+11.1%62.3%22.6%$2.32$928.0M

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$27.3B$27.0B – $27.4B$14.98$14.86 – $15.0820
FY27$29.6B$29.0B – $29.9B$16.71$15.48 – $17.0220
FY28$32.0B$32.0B – $32.0B$18.61$17.31 – $20.2920
FY29$34.9B$34.5B – $35.3B$20.83$20.48 – $21.0911
FY30$38.0B$37.5B – $38.3B$23.19$22.79 – $23.4811

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.31%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-7.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 347.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.785-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 28Robert S FletcherVP, Chief Legal Officer4.5K sh$1.4MSellMay 26Ronda E StrykerDirector310.0K sh$96.8MSellMay 11Fink M KathrynVP, Chief HR Officer8.7K sh$2.5M
+ 27 other (11 awards · 8 inkinds · 7 exempts · 1 gift) in window

See when $SYK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 208-K — Item 5.02: Officer or director change
AI summary

Stryker announced that VP and Chief Accounting Officer William E. Berry, Jr. will retire September 1, 2026, with Emily Baculik (age 46), VP Corporate Controller since November 2024, succeeding him as chief accounting officer on the same date. The planned transition ensures continuity in financial reporting oversight for the global medical technology company.

8-KShareholder voteMay 88-K — Item 5.07: Shareholder vote
SC 13D/AActivist amendmentApr 14SC 13D/A
8-K/APress release / Reg FD (amended)Apr 98-K/A — Item 1.05 · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 238-K — Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 128-K — Item 7.01: Press release / Reg FD
+ 12 other (3 13Gs · 2 routine 8-Ks · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfoliozacks.com·4d agoStryker expands Mako robotics portfolio with full market release of Mako RPSprnewswire.com·6d agoStryker: The Market Is Overreacting To One Disrupted Quarterseekingalpha.com·13d agoBeyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFszacks.com·13d agoICUI vs. SYK: Which Stock Should Value Investors Buy Now?zacks.com·13d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MDT$ABT$ISRG$BSX$BFLY$TMDX$BIO$ECOR
Voices on X · last 7 days

No standout posts about $SYK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport